^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    SLC35A2 overexpression

    i
    Other names: SLC35A2, Solute Carrier Family 35 Member A2, UGTL, UGT, UDP-Galactose Translocator, UDP-Gal-Tr, UGALT, UGAT, UGT1, UGT2, Solute Carrier Family 35 (UDP-Galactose Transporter), Member A2, Solute Carrier Family 35 (UDP-Galactose Transporter), Member 2, UDP-Galactose Transporter, CDG2M, CDGX
    Entrez ID:
    7355
    5ms
    SLC35A2 expression is associated with HER2 expression in breast cancer. (PubMed, Discov Oncol)
    These results suggest that SLC35A2 is overexpressed in breast cancer tissues compared to adjacent non-neoplastic tissues and may serve as a potential prognostic marker for HER2-positive subtype breast cancer. Furthermore, breast cancer patients with the HER2 positive subtype who exhibited decreased levels of SLC35A2 expression demonstrated improved long-term prognostic outcomes.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • SLC35A2 (Solute Carrier Family 35 Member A2)
    |
    HER-2 positive • HER-2 expression • SLC35A2 overexpression
    1year
    Comprehensive Analysis of SLC35A2 in Pan-Cancer and Validation of Its Role in Breast Cancer. (PubMed, J Inflamm Res)
    SLC35A2 has good diagnostic and prognostic values in multiple cancers and is closely related to tumor immune infiltration. In addition, SLA35A2 as an oncogene in breast cancer may be involved in the progression of epithelial mesenchymal transition (EMT).
    Journal • Tumor mutational burden • Pan tumor
    |
    TMB (Tumor Mutational Burden) • MSI (Microsatellite instability) • CDH1 (Cadherin 1) • SLC35A2 (Solute Carrier Family 35 Member A2) • CDH2 (Cadherin 2)
    |
    SLC35A2 overexpression